Back to results
US 2024/0191255 A1Published application
Adenoviral Vectors
AssigneeGene Bridges GMBH
InventorsAdrian Francis Stewart, Jun Fu, Anja Ehrhardt, Eric Ehrke-Schulz, Wenli Zhang
Life of this patent
Estimating the term…
Abstract
The invention relates to adenoviral vectors, cells for use in generating adenoviral vectors, methods for generating adenoviral vectors, and therapeutic uses of adenoviral vectors in gene therapy, tumour therapy and as vaccines.
Claims11
-73. (canceled)
A method for cloning an adenoviral sequence, wherein the adenoviral sequence is a full length adenoviral genome sequence, comprising:
- a) providing a first linear nucleic acid molecule which comprises the full length adenoviral genome sequence;
- b) providing a linearized medium copy plasmid which shares at least two regions of sequence homology with the first linear nucleic acid molecule;
- and
- c) bringing the first linear nucleic acid molecule and the linearized medium copy plasmid into contact in the presence of a 5′ to 3′ exonuclease and an annealing protein such that the first linear nucleic acid molecule and the linearized medium copy plasmid recombine to form a circular plasmid containing the full length adenoviral genome sequence;
- wherein the 5′ to 3′ exonuclease is RecE of SEQ ID NO:
- 1412, or a protein with at least 90% sequence identity to SEQ ID NO:1412, and the annealing protein is RecT,
- and wherein a first region of the at least two regions of sequence homology is a region with sequence homology to only the 5′ ITR of the adenoviral sequence in the first linear nucleic acid molecule, and a second region of the at least two regions of sequence homology is a region with sequence homology to only the 3′ ITR of the adenoviral sequence in the first linear nucleic acid molecule.
4 more elements
Dependencies are inferred from the claim text.